Anti-PSMA
Animals
Antigens, Surface
/ immunology
Cell Line, Tumor
Glutamate Carboxypeptidase II
/ immunology
Humans
Immunoconjugates
/ immunology
Iodine Radioisotopes
/ pharmacology
Male
Mice
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms
/ diagnosis
Radiopharmaceuticals
/ immunology
Single-Chain Antibodies
/ immunology
Tissue Distribution
124I
Antibody fragment
PCa
PET
scFv
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
30
05
2019
accepted:
15
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease and detection of metastatic lesions. Prostate-specific membrane antigen (PSMA) expression, directly related to androgen-independence, metastasis and progression, renders this tumour associate antigen a good target for the development of new radiopharmaceuticals for PET. Aim of this study was to demonstrate in a preclinical in vivo model (PSMA-positive versus PSMA-negative tumours) the targeting specificity and sensitivity of the anti-PSMA single-chain variable fragment (scFv) labelled with The The uptake fraction of Preclinical in vivo results of our immuno-PET reagent are highly promising. The target to background ratio is improved notably using PET compared to SPECT previously performed. These data suggest that, upon clinical confirmation of sensitivity and specificity, our anti-PSMA
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease and detection of metastatic lesions. Prostate-specific membrane antigen (PSMA) expression, directly related to androgen-independence, metastasis and progression, renders this tumour associate antigen a good target for the development of new radiopharmaceuticals for PET. Aim of this study was to demonstrate in a preclinical in vivo model (PSMA-positive versus PSMA-negative tumours) the targeting specificity and sensitivity of the anti-PSMA single-chain variable fragment (scFv) labelled with
METHODS
METHODS
The
RESULTS
RESULTS
The uptake fraction of
CONCLUSIONS
CONCLUSIONS
Preclinical in vivo results of our immuno-PET reagent are highly promising. The target to background ratio is improved notably using PET compared to SPECT previously performed. These data suggest that, upon clinical confirmation of sensitivity and specificity, our anti-PSMA
Identifiants
pubmed: 31337429
doi: 10.1186/s13046-019-1325-6
pii: 10.1186/s13046-019-1325-6
pmc: PMC6651934
doi:
Substances chimiques
Antigens, Surface
0
Immunoconjugates
0
Iodine Radioisotopes
0
Iodine-124
0
Radiopharmaceuticals
0
Single-Chain Antibodies
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
326Subventions
Organisme : Ministero della Salute
ID : RF-2016-02363661
Organisme : Fondazione Antonio Carlo Monzino
ID : N/A
Organisme : H2020 European Research Council
ID : 678109
Références
Cancer Res. 2005 Feb 1;65(3):727-31
pubmed: 15705868
BJU Int. 2006 May;97(5):923-31
pubmed: 16643472
Nucl Med Biol. 2007 Oct;34(7):757-78
pubmed: 17921028
BJU Int. 2008 Aug;102(4):446-51
pubmed: 18410442
J Exp Clin Cancer Res. 2008 Oct 17;27:52
pubmed: 18928537
Clin Oncol (R Coll Radiol). 2010 Feb;22(1):46-55
pubmed: 19948393
Semin Nucl Med. 2010 May;40(3):167-81
pubmed: 20350626
Eur Radiol. 2011 Dec;21(12):2604-17
pubmed: 21887484
Eur J Cancer. 2013 Jun;49(9):2223-32
pubmed: 23433847
J Urol. 2014 May;191(5):1439-45
pubmed: 24135437
J Nucl Med. 2014 Jun;55(6):995-1001
pubmed: 24700882
Contrast Media Mol Imaging. 2015 Jan-Feb;10(1):28-36
pubmed: 24764162
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105
pubmed: 25143071
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
Eur Urol. 2016 Aug;70(2):233-45
pubmed: 26215604
Immunol Lett. 2015 Nov;168(1):105-10
pubmed: 26404855
Int J Cancer. 2016 Mar 15;138(6):1388-400
pubmed: 26488767
Eur Urol. 2016 Jul;70(1):161-175
pubmed: 26850970
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Oncotarget. 2017 Feb 14;8(7):10919-10930
pubmed: 28051996
J Exp Clin Cancer Res. 2018 Mar 2;37(1):42
pubmed: 29499713
J Exp Clin Cancer Res. 2018 Jul 21;37(1):163
pubmed: 30031396
J Nucl Med. 2019 Jul;60(7):963-970
pubmed: 30552203
Urol Oncol. 2019 May 6;:null
pubmed: 31072791
J Nucl Med. 1986 Aug;27(8):1293-9
pubmed: 3734902
J Exp Med. 1983 Aug 1;158(2):413-27
pubmed: 6886623
Br J Cancer. 1993 Oct;68(4):684-90
pubmed: 8398694
Prostate. 1998 Dec 1;37(4):261-9
pubmed: 9831223